Angel News

Angel News

Back to Homepage

15th June 2020

Zelluna Immunotherapy raises funds for allogeneic cell therapies

Zelluna Immunotherapy, a T Cell Receptor (TCR) cell therapy company, has completed a fundraise to fully focus on the development of its proprietary TCR guided Natural Killer (NK) cell therapy platform (TCR-NK) for the treatment of cancers.  

A total of approximately EUR 7.5 million has been raised in equity financing and public grants. Zelluna’s strategy is to concentrate on the development of TCR-NK cell therapy products based on its proprietary technology platform, where TCRs are functionally expressed in NK cells. The combination of the broad target range of TCRs with the inherent anti-tumor activity and allogeneic nature of NK cells could offer novel, safe, and effective “off the shelf” cell therapy treatments for solid cancer patients. 


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage